


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of the Claims:**

Claims 1-33 (Deleted).

34. (New) A compound having the following formula:



(I)

or a salt thereof.

35. (New) The compound of claim 34, wherein the compound is substantially pure.
36. (New) A pharmaceutical composition comprising the compound of claim 34 and at least one pharmaceutically acceptable carrier, filler or diluent.
37. (New) The pharmaceutical composition of claim 36, wherein the compound is present in an enantiomeric excess of at least 90%.

38. (New) A method of treating a subject suffering from a disease or disorder comprising administering to the subject a therapeutically effective amount of the compound of claim 34, wherein the disease or disorder is selected from the group consisting of schizophrenia, an anxiety disorder, an affective disorder, depression, a psychotic disorder, a sleep disturbance, migraine, neuroleptic-induced parkinsonism, a disorder exhibiting psychotic symptoms, an abuse disorder, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder and mania in bipolar disorder.
39. (New) The method of claim 38, wherein the disease or disorder is schizophrenia or a psychotic disorder.
40. (New) The method of claim 39, wherein the schizophrenia comprises positive symptoms.
41. (New) The method of claim 39, wherein the schizophrenia comprises negative symptoms.
42. (New) The method of claim 39, wherein the schizophrenia comprises depressive symptoms.
43. (New) The method of claim 38, wherein the subject is treated with at least one other medicament.

44. (New) A method of treating a subject suffering from a disease or disorder comprising administering to the subject a therapeutically effective amount of the compound of claim 34, wherein the disease or disorder is selected from the group consisting of schizophrenia, an anxiety disorder, an affective disorder, depression, a psychotic disorder, a sleep disturbance, migraine, neuroleptic-induced parkinsonism, a disorder exhibiting psychotic symptoms, an abuse disorder, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder and mania in bipolar disorder, and wherein the compound is present in an enantiomeric excess of at least 90%.
45. (New) The method of claim 38, wherein the abuse disorder is selected from the group consisting of cocaine abuse, nicotine abuse and alcohol abuse.
46. The compound of claim 34, wherein the compound is *trans*-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine or a pharmaceutically acceptable salt thereof.
47. (New) A pharmaceutical composition comprising the compound of claim 46 and at least one pharmaceutically acceptable carrier, diluent or filler.
48. (New) A method of treating a subject suffering from a disease or disorder comprising administering to the subject a therapeutically effective amount of the compound of claim 46, wherein the disease or disorder is selected from the group consisting of a disorder exhibiting psychotic symptoms, schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder, mania in bipolar disorder, an anxiety disorder, an affective disorder,

depression, a sleep disturbance, migraine, neuroleptic-induced parkinsonism, and an abuse disorder.

49. (New) The method of claim 48, wherein the abuse disorder is selected from the group consisting of cocaine abuse, nicotine abuse and alcohol abuse.